Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Maplirpacept by Pfizer for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
Maplirpacept is under clinical development by Pfizer and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to GlobalData,...
Maplirpacept by Pfizer for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
Maplirpacept is under clinical development by Pfizer and currently in Phase I for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According to...
Maplirpacept by Pfizer for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Maplirpacept is under clinical development by Pfizer and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)....
Maplirpacept by Pfizer for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
Maplirpacept is under clinical development by Pfizer and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL). According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Pfizer's Maplirpacept?
Maplirpacept is a fusion protein commercialized by Pfizer, with a leading Phase II program in Primary Mediastinal B-Cell Lymphoma. According...
Maplirpacept by Pfizer for Refractory Multiple Myeloma: Likelihood of Approval
Maplirpacept is under clinical development by Pfizer and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData, Phase...